Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?

A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.

RacingCar
Arecor Feels The Need For Speed With Ultra-Rapid Acting Insulin Product • Source: Shutterstock

More from Clinical Trials

More from R&D